Clinical Trials Logo

Acute Mountain Sickness (AMS) clinical trials

View clinical trials related to Acute Mountain Sickness (AMS).

Filter by:
  • None
  • Page 1

NCT ID: NCT04993729 Recruiting - Clinical trials for Acute Mountain Sickness (AMS)

Safety and Efficacy of T89 in the Prevention and Treatment of Adults With Acute Mountain Sickness (AMS)

Start date: July 21, 2021
Phase: Phase 3
Study type: Interventional

The specific aim of this double blind, randomized phase III trial is to evaluate the safety and efficacy of T89 in preventing Acute Mountain Sickness (AMS) and relieving the symptoms of AMS after rapid ascent.

NCT ID: NCT03552263 Completed - Clinical trials for Acute Mountain Sickness (AMS)

Safety and Efficacy of T89 in Prevention and Treatment of Adults With Acute Mountain Sickness (AMS)

Start date: June 7, 2018
Phase: Phase 2
Study type: Interventional

Acute mountain sickness (AMS) is one of three syndromes of altitude illness. It is very common when people venture over 2500 meters altitude. This illness is mainly induced by acute exposure to low partial pressure of oxygen at high altitude that will cause a pathological effect on humans. T89 capsule is a modernized industrialized traditional Chinese herbal medicine. It is a botanical drug for oral use. In recent years, several literatures and clinical studies have showed that oral administration of T89 may provide substantial benefits in the prevention or alleviation of symptoms associated with acute mountain sickness (AMS), including nausea, vomiting, headache, dizziness, fatigue, and sleep disturbance. Such effect was also observed in a pilot clinical study recently conducted in Tibet in China. This study is a prospective, double-blind, randomized, placebo-controlled phase 2 clinical trial having three arms including T89 low-dose, T89 high-dose and a placebo controlled group. People will be screened against the inclusion/exclusion criteria after informed consent signed. Eligible subjects will be randomly assigned into one of three arms and instructed to use T89 orally twice daily for 14 days (Days 1-14) before ascending, and 5 days after ascending during the observation period (Days 15-19). The primary efficacy parameter is Lake Louise Scoring System (LLSS) which will be evaluated by subject-self and principal investigator in clinic.

NCT ID: NCT01682551 Not yet recruiting - Clinical trials for Acute Mountain Sickness (AMS)

Evaluation of the Prevention and Treatment Effects of Chinese Medicine on High Altitude Illness

Start date: September 2012
Phase: Phase 2
Study type: Interventional

This trial is aimed to evaluate the effects of "Wu Zhu Yu Tang" on the prevention of Acute Mountain Sickness(AMS).